INTRODUCTION {#s0}
============

Multidrug resistance among Gram-negative organisms is a global problem, with rates of infections caused by multidrug-resistant (MDR) Gram-negative bacteria increasing worldwide ([@B1][@B2][@B3]). MDR Gram-negative pathogens, such as *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and the *Enterobacteriaceae*, are associated with increased lengths of hospitalization, higher health care costs, and greater rates of mortality ([@B2], [@B4][@B5][@B6]). These organisms have been highlighted as clinically important bacteria, and some are included among the ESKAPE pathogens (an acronym for *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *A. baumanii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.) ([@B7]).

Tigecycline is a broad-spectrum glycylcycline antimicrobial agent with *in vitro* activity against both Gram-positive and Gram-negative organisms. Tigecycline has been approved in the United States and Europe for the treatment of complicated skin and intra-abdominal infections and also in the United States for community-acquired bacterial pneumonia ([@B8], [@B9]). The *in vitro* activity of tigecycline is monitored globally, alongside comparator agents, against clinical Gram-positive and Gram-negative isolates as part of the Tigecycline Evaluation and Surveillance Trial (TEST). This study describes the activity of tigecycline against MDR Gram-negative isolates collected globally between 2004 and 2014. Isolates collected during the earlier years of the study period have been included in previous TEST publications, including reports focused on MDR *A. baumannii* ([@B10]) and MDR *Enterobacteriaceae* ([@B11]) isolates that were collected in the United States between 2004 and 2006 and on MDR Gram-negative isolates collected globally between 2004 and 2013 ([@B12]).

RESULTS {#s1}
=======

Between 2004 and 2014, the majority of TEST centers were located in North America and Europe (37% and 36%, respectively). Over the study period, 13% (21,967/170,759) of Gram-negative isolates collected globally were MDR.

*Acinetobacter baumannii*. {#s1.1}
--------------------------

In total, 18,741 isolates of *A. baumannii* were collected globally, of which 44% were reported to be MDR ([Table 1](#tab1){ref-type="table"}). Global rates of MDR *A. baumannii* isolates increased during the study period, from 23% in 2004 to 63% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). By region, overall multidrug resistance among *A. baumannii* was lowest in North America (31%) ([Table 1](#tab1){ref-type="table"}). More than 50% of *A. baumannii* isolates collected in Africa, the Middle East, and Latin America were MDR.

###### 

Regional and global rates of MDR Gram-negative isolates collected between 2004 and 2014

  Organism and region         No. of centers[^a^](#ngtab1.1){ref-type="table-fn"}   No. of MDR isolates   Total no. of isolates   \% MDR
  --------------------------- ----------------------------------------------------- --------------------- ----------------------- --------
  *Acinetobacter baumannii*                                                                                                       
      Africa                  17                                                    249                   407                     61.2
      Asia-Pacific Rim        43                                                    596                   1,229                   48.5
      Europe                  190                                                   3,617                 8,409                   43.0
      Latin America           58                                                    1,560                 2,213                   70.5
      Middle East             20                                                    499                   718                     69.5
      North America           169                                                   1,773                 5,765                   30.8
      Global                  497                                                   8,294                 18,741                  44.3
  *Pseudomonas aeruginosa*                                                                                                        
      Africa                  16                                                    73                    558                     13.1
      Asia-Pacific Rim        46                                                    327                   1,772                   18.5
      Europe                  192                                                   1,777                 14,951                  11.9
      Latin America           66                                                    913                   3,340                   27.3
      Middle East             21                                                    129                   989                     13.0
      North America           180                                                   732                   11,176                  6.5
      Global                  521                                                   3,951                 32,786                  12.1
  *Escherichia coli*                                                                                                              
      Africa                  13                                                    58                    731                     7.9
      Asia-Pacific Rim        41                                                    299                   2,178                   13.7
      Europe                  190                                                   1,323                 19,242                  6.9
      Latin America           65                                                    795                   4,492                   17.7
      Middle East             23                                                    190                   1,301                   14.6
      North America           157                                                   557                   14,317                  3.9
      Global                  489                                                   3,222                 42,261                  7.6
  *Klebsiella pneumoniae*                                                                                                         
      Africa                  16                                                    111                   668                     16.6
      Asia-Pacific Rim        43                                                    299                   1,940                   15.4
      Europe                  175                                                   1,778                 13,936                  12.8
      Latin America           62                                                    709                   3,704                   19.1
      Middle East             21                                                    231                   1,142                   20.2
      North America           145                                                   767                   11,498                  6.7
      Global                  462                                                   3,895                 32,888                  11.8
  *Klebsiella oxytoca*                                                                                                            
      Africa                  2                                                     2                     85                      2.4
      Asia-Pacific Rim        8                                                     14                    245                     5.7
      Europe                  62                                                    113                   4,639                   2.4
      Latin America           20                                                    29                    395                     7.3
      Middle East             8                                                     14                    106                     13.2
      North America           22                                                    31                    2,530                   1.2
      Global                  122                                                   203                   8,000                   2.5
  *Enterobacter aerogenes*                                                                                                        
      Africa                  3                                                     5                     94                      5.3
      Asia-Pacific Rim        17                                                    25                    490                     5.1
      Europe                  72                                                    193                   3,733                   5.2
      Latin America           25                                                    72                    583                     12.3
      Middle East             8                                                     13                    256                     5.1
      North America           48                                                    73                    3,297                   2.2
      Global                  173                                                   381                   8,453                   4.5
  *Enterobacter cloacae*                                                                                                          
      Africa                  11                                                    37                    494                     7.5
      Asia-Pacific Rim        36                                                    122                   1,437                   8.5
      Europe                  168                                                   978                   13,205                  7.4
      Latin America           55                                                    387                   2,771                   14.0
      Middle East             15                                                    49                    815                     6.0
      North America           143                                                   448                   8,908                   5.0
      Global                  428                                                   2,021                 27,630                  7.3

The number of TEST centers submitting MDR isolates. Not all centers submitted isolates during all study years. The Asia-Pacific Rim centers did not participate in TEST after 2010.

![Changes in global rates of MDR Gram-negative isolates collected between 2004 and 2014.](sph0011722200001){#fig1}

Overall, 95% of MDR *A. baumannii* isolates were resistant to ceftriaxone, and approximately 90% of isolates were resistant to ceftazidime, levofloxacin, meropenem, and piperacillin-tazobactam ([Table 2](#tab2){ref-type="table"}). Global resistance to levofloxacin increased significantly from 92% (283/309) in 2004 to 96% (430/447) in 2014, and resistance to piperacillin-tazobactam increased significantly from 82% (252/309) in 2004 to 94% (422/447) in 2014 (*P* \< 0.0001) ([Table 3](#tab3){ref-type="table"}). The lowest levels of global resistance were reported for minocycline (13%). The lowest MIC~90~ value was observed for tigecycline (2 mg/liter), for which no breakpoints are available against *A. baumannii*.

###### 

Global antimicrobial activity against MDR Gram-negative isolates collected between 2004 and 2014

  Organism (no. of isolates) and antimicrobial agent           MIC (mg/liter) data   Susceptibility[^a^](#ngtab2.1){ref-type="table-fn"}                                                     
  ------------------------------------------------------------ --------------------- ----------------------------------------------------- ------------------------------------------ ------ ------
  *Acinetobacter baumannii* (8,294)                                                                                                                                                          
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          20.1                                       7.7    72.2
      Amoxicillin-clavulanic acid                              ≥64                   1 to ≥64                                              ---[^b^](#ngtab2.2){ref-type="table-fn"}   ---    ---
      Ampicillin                                               ≥64                   ≤0.5 to ≥64                                           ---                                        ---    ---
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           5.3                                        13.6   81.2
      Ceftazidime                                              ≥64                   ≤1 to ≥64                                             4.1                                        5.3    90.7
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         0.7                                        4.8    94.6
      Levofloxacin                                             ≥16                   0.03 to ≥16                                           2.3                                        7.9    89.8
      Meropenem (7,338)[^c^](#ngtab2.3){ref-type="table-fn"}   ≥32                   ≤0.06 to ≥32                                          6.9                                        3.0    90.1
      Minocycline                                              16                    ≤0.5 to ≥32                                           68.6                                       18.9   12.6
      Piperacillin-tazobactam                                  ≥256                  ≤0.06 to ≥256                                         2.7                                        6.4    90.9
      Tigecycline                                              2                     ≤0.008 to ≥32                                         ---                                        ---    ---
  *Pseudomonas aeruginosa* (3,951)                                                                                                                                                           
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          46.1                                       10.2   43.7
      Amoxicillin-clavulanic acid                              ≥64                   1 to ≥64                                              ---                                        ---    ---
      Ampicillin                                               ≥64                   ≤0.5 to ≥64                                           ---                                        ---    ---
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           7.7                                        22.5   69.8
      Ceftazidime                                              ≥64                   ≤1 to ≥64                                             11.5                                       11.0   77.5
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         ---                                        ---    ---
      Levofloxacin                                             ≥16                   0.03 to ≥16                                           2.1                                        1.5    96.4
      Meropenem (3,392)[^c^](#ngtab2.3){ref-type="table-fn"}   ≥32                   ≤0.06 to ≥32                                          4.5                                        2.9    92.6
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           ---                                        ---    ---
      Piperacillin-tazobactam                                  ≥256                  0.25 to ≥256                                          10.8                                       22.3   66.9
      Tigecycline                                              ≥32                   ≤0.008 to ≥32                                         ---                                        ---    ---
  *Escherichia coli* (3,222)                                                                                                                                                                 
      Amikacin                                                 32                    ≤0.5 to ≥128                                          88.3                                       2.7    9.0
      Amoxicillin-clavulanic acid                              ≥64                   1 to ≥64                                              22.7                                       36.8   40.4
      Ampicillin                                               ≥64                   ≤0.5 to ≥64                                           0.6                                        0.1    99.3
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           49.6                                       12.6   37.8
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         41.5                                       1.6    57.0
      Levofloxacin                                             ≥16                   ≤0.008 to ≥16                                         1.4                                        0.2    98.4
      Meropenem (2,814)[^c^](#ngtab2.3){ref-type="table-fn"}   0.25                  ≤0.06 to ≥32                                          92.9                                       1.1    6.0
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           5.2                                        2.0    92.8
      Piperacillin-tazobactam                                  ≥256                  0.25 to ≥256                                          68.2                                       14.1   17.7
      Tigecycline                                              1                     ≤0.008 to ≥32                                         99.5                                       0.2    0.2
  *Klebsiella pneumoniae* (3,895)                                                                                                                                                            
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          68.5                                       11.8   19.7
      Amoxicillin-clavulanic acid                              ≥64                   0.5 to ≥64                                            10.7                                       19.5   69.8
      Ampicillin                                               ≥64                   2 to ≥64                                              0.0                                        0.1    99.9
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           15.0                                       10.2   74.8
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         10.1                                       0.9    89.0
      Levofloxacin                                             ≥16                   0.03 to ≥16                                           4.4                                        1.3    94.3
      Meropenem (3,578)[^c^](#ngtab2.3){ref-type="table-fn"}   ≥32                   ≤0.06 to ≥32                                          57.0                                       3.5    39.5
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           25.5                                       9.8    64.7
      Piperacillin-tazobactam                                  ≥256                  0.12 to ≥256                                          21.5                                       13.7   64.8
      Tigecycline                                              4                     ≤0.008 to ≥32                                         83.0                                       11.3   5.7
  *Klebsiella oxytoca* (203)                                                                                                                                                                 
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          76.8                                       5.4    17.7
      Amoxicillin-clavulanic acid                              ≥64                   0.25 to ≥64                                           12.8                                       21.7   65.5
      Ampicillin                                               ≥64                   32 to ≥64                                             0.0                                        0.0    100
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           25.6                                       28.1   46.3
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         13.3                                       0.0    86.7
      Levofloxacin                                             ≥16                   0.06 to ≥16                                           5.4                                        3.4    91.1
      Meropenem (180)[^c^](#ngtab2.3){ref-type="table-fn"}     8                     ≤0.06 to ≥32                                          80.0                                       2.2    17.8
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           7.4                                        6.9    85.7
      Piperacillin-tazobactam                                  ≥256                  ≤0.06 to ≥256                                         34.5                                       12.8   52.7
      Tigecycline                                              4                     0.12 to 8                                             81.3                                       12.8   5.9
  *Enterobacter aerogenes* (381)                                                                                                                                                             
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          74.0                                       5.0    21.0
      Amoxicillin-clavulanic acid                              ≥64                   2 to ≥64                                              2.1                                        4.5    93.4
      Ampicillin                                               ≥64                   16 to ≥64                                             0.0                                        0.5    99.5
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           38.3                                       21.3   40.4
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         12.3                                       0.8    86.9
      Levofloxacin                                             ≥16                   0.06 to ≥16                                           13.9                                       2.9    83.2
      Meropenem (321)[^c^](#ngtab2.3){ref-type="table-fn"}     16                    ≤0.06 to ≥32                                          67.9                                       3.1    29.0
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           15.0                                       8.1    76.9
      Piperacillin-tazobactam                                  ≥256                  1 to ≥256                                             28.6                                       30.2   41.2
      Tigecycline                                              8                     0.015 to 16                                           66.9                                       20.7   12.3
  *Enterobacter cloacae* (2,021)                                                                                                                                                             
      Amikacin                                                 ≥128                  ≤0.5 to ≥128                                          75.4                                       4.4    20.2
      Amoxicillin-clavulanic acid                              ≥64                   0.25 to ≥64                                           0.5                                        1.9    97.6
      Ampicillin                                               ≥64                   ≤0.5 to ≥64                                           0.4                                        0.5    99.0
      Cefepime                                                 ≥64                   ≤0.5 to ≥64                                           23.5                                       30.8   45.7
      Ceftriaxone                                              ≥128                  ≤0.06 to ≥128                                         7.7                                        1.9    90.5
      Levofloxacin                                             ≥16                   ≤0.008 to ≥16                                         11.2                                       3.4    85.4
      Meropenem (1,717)[^c^](#ngtab2.3){ref-type="table-fn"}   8                     ≤0.06 to ≥32                                          79.1                                       3.8    17.1
      Minocycline                                              ≥32                   ≤0.5 to ≥32                                           5.3                                        6.0    88.6
      Piperacillin-tazobactam                                  ≥256                  ≤0.06 to ≥256                                         26.0                                       20.8   53.2
      Tigecycline                                              8                     0.015 to ≥32                                          64.4                                       20.3   15.3

S, susceptible; I, intermediate susceptibility; R, resistant.

---, no breakpoints available.

Susceptibility data for imipenem were collected from 2004 to 2006, after which time imipenem was replaced with meropenem.

###### 

Statistically significant changes in global antimicrobial activity among MDR Gram-negative isolates collected between 2004 and 2014, by study year

  Species and antimicrobial agent[^a^](#ngtab3.1){ref-type="table-fn"}   \% of isolates resistant to the indicated drug in:   *P* value[^b^](#ngtab3.2){ref-type="table-fn"}   Change in resistance                                                                               
  ---------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ---------------------- ------------ ------- ------- ------- ------ ------ ------ ------ ---------- -----------
  *A. baumannii*                                                         309                                                  310                                              645                    987          1,134   1,379   1,112   588    661    722    447               
      Cefepime                                                           79.0                                                 83.9                                             82.0                   85.4         72.4    72.2    81.3    85.5   89.0   90.3   87.7   \<0.0001   Increased
      Levofloxacin                                                       91.6                                                 92.6                                             83.9                   87.1         88.4    89.2    88.0    91.7   93.2   94.5   96.2   \<0.0001   Increased
      Meropenem[^d^](#ngtab3.3){ref-type="table-fn"}                     *---[^c^](#ngtab3.4){ref-type="table-fn"}* (2)       89.5 (19)                                        87.6 (307)             86.8 (967)   85.4    85.1    91.6    95.1   95.3   96.8   97.5   \<0.0001   Increased
      Minocycline                                                        10.4                                                 8.4                                              9.8                    11.3         11.3    10.9    17.0    13.3   13.8   15.2   13.9   \<0.0001   Increased
      Pip-taz                                                            81.6                                                 66.1                                             80.9                   87.1         93.1    93.0    95.8    94.7   94.6   96.3   94.4   \<0.0001   Increased
                                                                                                                                                                                                                                                                                  
  *P. aeruginosa*                                                        10                                                   7                                                147                    464          656     726     541     256    189    251    145               
      Meropenem[^d^](#ngtab3.3){ref-type="table-fn"}                     ---                                                  ---                                              95.9                   91.2         90.2    91.5    90.4    96.5   97.4   96.4   98.6   \<0.0001   Increased
                                                                                                                                                                                                                                                                                  
  *E. coli*                                                              117                                                  116                                              268                    403          578     651     479     195    154    162    99                
      Amikacin                                                           4.3                                                  10.3                                             8.6                    14.1         13.7    10.0    4.8     2.1    1.9    7.4    6.1    \<0.0001   Decreased
      Cefepime                                                           15.4                                                 27.6                                             34.3                   38.7         39.8    38.2    37.4    40.5   45.5   41.4   46.5   \<0.0001   Increased
      Tigecycline                                                        0.0                                                  0.0                                              0.0                    0.0          0.0     0.2     0.2     1.0    1.3    1.2    0.0    \<0.01     Increased
                                                                                                                                                                                                                                                                                  
  *K. pneumoniae*                                                        83                                                   151                                              281                    410          599     717     614     306    307    280    147               
      Amikacin                                                           14.5                                                 25.8                                             26.0                   28.0         29.5    24.1    10.1    9.5    9.4    16.4   8.2    \<0.0001   Decreased
      Amoxy-clav                                                         55.4                                                 66.9                                             65.5                   68.5         67.1    67.2    70.7    73.9   77.2   76.1   76.9   \<0.0001   Increased
      Cefepime                                                           61.4                                                 69.5                                             71.2                   74.6         73.6    71.0    72.1    76.8   82.7   85.0   88.4   \<0.0001   Increased
      Levofloxacin                                                       85.5                                                 90.7                                             91.1                   93.7         93.5    94.1    97.7    94.8   95.4   95.0   96.6   \<0.0001   Increased
      Meropenem[^d^](#ngtab3.3){ref-type="table-fn"}                     41.2 (17)                                            51.7 (29)                                        45.2 (155)             36.1 (407)   26.4    30.3    28.2    52.6   62.5   65.0   63.3   \<0.0001   Increased
      Minocycline                                                        68.7                                                 53.0                                             60.9                   65.1         77.0    73.9    78.5    54.2   41.4   42.9   40.8   \<0.0001   Decreased
      Pip-taz                                                            50.6                                                 55.6                                             64.8                   65.9         63.1    59.1    61.6    69.0   75.9   75.7   74.8   \<0.0001   Increased
                                                                                                                                                                                                                                                                                  
  *K. oxytoca*                                                           2                                                    8                                                16                     30           39      50      25      13     7      10     3                 
      Amikacin                                                           ---                                                  ---                                              43.8                   30.0         25.6    10.0    8.0     0.0    ---    ---    ---    \<0.001    Decreased
                                                                                                                                                                                                                                                                                  
  *E. cloacae*                                                           78                                                   124                                              181                    234          339     379     280     131    90     128    57                
      Cefepime                                                           35.9                                                 29.8                                             48.1                   48.3         49.9    43.0    42.5    41.2   47.8   57.8   63.2   \<0.01     Increased

For each bacterial species, data in the shaded rows indicate the species and the number of isolates collected (by year). Abbreviations for antimicrobial agents: Pip-taz, piperacillin-tazobactam; Amoxy-clav, amoxicillin-clavulanic acid.

A cutoff value of *P* \< 0.01 was used for statistical significance testing.

---, the percent resistance was not calculated when ≤10 isolates of the species were collected that year.

Susceptibility data for imipenem were collected from 2004 to 2006, after which time imipenem was replaced with meropenem. The values in parentheses indicate the numbers of isolates tested against meropenem.

*Pseudomonas aeruginosa*. {#s1.2}
-------------------------

MDR isolates accounted for 12% of the 32,786 *P. aeruginosa* total isolates submitted ([Table 1](#tab1){ref-type="table"}). Global rates of MDR *P. aeruginosa* increased from 9% in the 2004-2005 period to 17% in the 2008-2010 period, and then the rate decreased to 8% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). Regionally, overall rates of multidrug resistance among *P. aeruginosa* were lowest in North America (7%) and highest in Latin America (27%) ([Table 1](#tab1){ref-type="table"}). Among MDR *P. aeruginosa* isolates, the highest levels of global resistance were reported to meropenem and levofloxacin (92% to 96%) ([Table 2](#tab2){ref-type="table"}). All agents had limited activity against isolates of MDR*P. aeruginosa* (MIC~90~, ≥16 mg/liter).

*Escherichia coli*. {#s1.3}
-------------------

Participating centers submitted a total of 42,261 *E. coli* isolates, of which 8% were MDR ([Table 1](#tab1){ref-type="table"}). Globally, rates of MDR *E. coli* increased from 5% in 2004 to 12% in the 2008-2009 period, and then decreased to 4% in the 2013-2014 period ([Fig. 1](#fig1){ref-type="fig"}). Regional percentages of MDR *E. coli* ranged from 4% in North America to 18% in Latin America ([Table 1](#tab1){ref-type="table"}). Globally, nearly all MDR *E. coli* isolates tested were resistant to levofloxacin and ampicillin (≥98%), and 93% of isolates were resistant to minocycline ([Table 2](#tab2){ref-type="table"}). Global resistance to cefepime increased significantly from 15% (18/117) in 2004 to 46% (46/99) in 2014 (*P* \< 0.0001) ([Table 3](#tab3){ref-type="table"}). The lowest level of resistance globally was to tigecycline (0.2%). No tigecycline-resistant isolates were identified between 2004 and 2008; however, eight resistant isolates were identified across regions between 2009 and 2013 (Africa in 2012 \[*n* = 1\], Europe in 2010 \[*n* = 1\], Latin America in 2009 \[*n* = 1\], the Middle East in 2011 \[*n* = 1\], and North America in 2011 \[*n* = 1\], 2012 \[*n* = 1\], and 2013 \[*n* = 2\]). This change was statistically significant (*P* \< 0.01) ([Table 3](#tab3){ref-type="table"}).

*Klebsiella pneumoniae*. {#s1.4}
------------------------

Multidrug resistance was reported in 12% of 32,888 of *K. pneumoniae* isolates submitted globally ([Table 1](#tab1){ref-type="table"}). During the study period, global rates of MDR *K. pneumoniae* increased from 4% in 2004 to 18% in 2010, and then the rate decreased to 8% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). By region, the lowest rates of MDR *K. pneumoniae* were found in North America (7%), with the highest rates in Latin America and the Middle East (19% and 20%, respectively) ([Table 1](#tab1){ref-type="table"}). High levels of global resistance were reported to ceftriaxone and levofloxacin (89% and 94%, respectively) ([Table 2](#tab2){ref-type="table"}). Global resistance to amoxicillin-clavulanic acid, cefepime, levofloxacin, and piperacillin-tazobactam increased significantly during the study period: amoxicillin-clavulanic acid, 55% (46/83) in 2004 to 77% (113/147) in 2014; cefepime, 61% (51/83) in 2004 to 88% (130/147) in 2014; levofloxacin, 86% (71/83) in 2004 to 97% (142/147) in 2014; piperacillin-tazobactam, 51% (42/83) in 2004 to 75% (110/147) in 2014 (*P* \< 0.0001) ([Table 3](#tab3){ref-type="table"}). The lowest rate of resistance among MDR*K. pneumoniae* was to tigecycline (6%).

*Klebsiella oxytoca*. {#s1.5}
---------------------

Over the study period, 8,000 isolates of *K. oxytoca* were submitted globally, of which 2.5% were MDR ([Table 1](#tab1){ref-type="table"}). The global rates of MDR *K. oxytoca* increased from 0.4% in 2004 to 5% in the 2008-2009 period and then decreased to 0.6% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). The highest percentages of MDR *K. oxytoca* isolates were reported in the Middle East (13%), while rates in all other regions were ≤7% ([Table 1](#tab1){ref-type="table"}). More than 80% of MDR *K. oxytoca* isolates collected globally were resistant to minocycline, ceftriaxone, and levofloxacin (86% to 91%) ([Table 2](#tab2){ref-type="table"}). The lowest rate of resistance was to tigecycline (6%).

*Enterobacter aerogenes*. {#s1.6}
-------------------------

Overall, 4.5% of 8,453 *E. aerogenes* isolates collected from all regions were MDR ([Table 1](#tab1){ref-type="table"}). Globally, the rates of MDR *E. aerogenes* increased from 3% in 2004 to 9% in 2008 but then decreased to 1% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). There was a rate of 12% MDR *E. aerogenes* in Latin America and a rate of ≤5% in all other regions ([Table 1](#tab1){ref-type="table"}). More than 80% of isolates were resistant to levofloxacin and ceftriaxone (83% and 87%, respectively) ([Table 2](#tab2){ref-type="table"}). The lowest levels of resistance were reported to tigecycline (12%), followed by amikacin (21%).

*Enterobacter cloacae*. {#s1.7}
-----------------------

Among the 27,630 isolates of *E. cloacae* submitted globally, a total of 7% were MDR ([Table 1](#tab1){ref-type="table"}). Global rates of MDR *E. cloacae* increased from 4.5% in 2004 to 10% in the 2008-2009 period, and then decreased to 4% in 2014 ([Fig. 1](#fig1){ref-type="fig"}). In Latin America, 14% of *E. cloacae* isolates were MDR, compared with \<9% of isolates in all other regions ([Table 1](#tab1){ref-type="table"}). The majority of MDR *E. cloacae* isolates collected globally were resistant to levofloxacin (85%), minocycline (89%), and ceftriaxone (90%) ([Table 2](#tab2){ref-type="table"}). Global resistance to cefepime increased significantly, from 36% (28/78) in 2004 to 63% (36/57) in 2014 (*P* \< 0.01) ([Table 3](#tab3){ref-type="table"}). Resistance to tigecycline was the lowest reported rate (15%).

DISCUSSION {#s2}
==========

This study describes the global rates of multidrug resistance among a selection of clinically important Gram-negative organisms collected between 2004 and 2014, and it shows the *in vitro* antimicrobial activity of tigecycline and a panel of other contemporary antimicrobial agents against these resistant isolates.

Tigecycline retained *in vitro* activity against the majority of MDR organisms collected between 2004 and 2014, with the exception of *P. aeruginosa* (MIC~90~, ≥32 mg/liter), against which tigecycline is known to have limited activity ([@B13]). Furthermore, none of the antimicrobial agents tested in the present study demonstrated potent *in vitro* activity against MDR *P. aeruginosa*, which was highlighted among the ESKAPE organisms as a cause for global concern ([@B7]). Against MDR *A. baumannii*, another of the ESKAPE pathogens, tigecycline had the lowest MIC~90~ (2 mg/liter) of the agents on the TEST panel. This MIC~90~ was comparable with that reported from a global study of *A. baumannii* isolates collected between 2005 and 2009, which showed that tigecycline inhibited 95% of MDR *Acinetobacter* spp. isolates at ≤2 mg/liter ([@B14]). Also, a study by Mammina et al. ([@B15]) of MDR *A. baumannii* from Palermo, Italy, reported tigecycline MICs between ≤0.5 mg/liter and 4 mg/liter.

Among the MDR *Enterobacteriaceae* collected in this study, rates of resistance were lowest to tigecycline. The overall global rates of tigecycline resistance among MDR *Enterobacteriaceae* were 15% (357/2,402) for *Enterobacter* spp., 6% (235/4,098) for *Klebsiella* spp., and 0.2% (8/3,222) for *E. coli*. Although the highest rates of tigecycline resistance among MDR *Enterobacteriaceae* were recorded for *Enterobacter* spp., the yearly rates of resistance among *E. aerogenes* and *E. cloacae* isolates fluctuated between 1% and 42% during the study period, and this could be explained by the low numbers of isolates submitted in some years. By year, the number of MDR *E. aerogenes* isolates collected ranged from 6 in 2014 to 83 in 2008. Yearly totals of MDR *E. cloacae* isolates were higher than those for MDR *E. aerogenes* isolates, but these totals only exceeded 200 isolates in four out of seven study years (2007 to 2010).

The overall global rate of tigecycline resistance among isolates of MDR *Klebsiella* spp. in the current study was 6% (*K. oxytoca*, 12/203; *K. pneumoniae*, 223/3,895). For MDR *K. oxytoca* isolates, the overall rate of tigecycline resistance may be difficult to interpret due to low isolate numbers (≤50 isolates collected per study year). Furthermore, tigecycline-resistant isolates were only identified in 2006 (19% \[3/16\]), 2008 (10% \[4/39\]), 2009 (4% \[2/50\]), and 2011 (23% \[3/13\]). Two of the three tigecycline-resistant *K. oxytoca* isolates collected in North America and Europe in 2006 and 2008, respectively, were submitted by the same center from each region. This suggests a localized incidence of tigecycline resistance during these two study years.

Higher numbers of MDR *K. pneumoniae* isolates were collected than numbers of MDR *K. oxytoca* isolates, and global rates of tigecycline-resistant MDR *K. pneumoniae* isolates ranged from 3% (4/147) to 11% (9/83). Despite this, the rates of tigecycline-resistant MDR *K. pneumoniae* isolates decreased from 9% (27/307) in 2012 to 3% (4/147) in 2014, which may signify the start of a decline in global resistance. Further surveillance will be needed to follow this trend. In their study of *bla*~KPC~-carrying *K. pneumoniae* in Palermo, Italy, Bonura et al. ([@B16]) reported a shift toward a polyclonal epidemic, which highlights that the evolution of resistance is complex and that the importance of changing patterns of resistance should not be underestimated.

In this study, the identification of tigecycline-resistant MDR *E. coli* from 2009 onwards indicates that these organisms have recently acquired mechanisms of resistance to the glycylcyclines. In the literature, occurrences of emerging tigecycline resistance among patients with *E. coli* infections have been reported in the United Kingdom ([@B17]) and in Italy ([@B18]). In both cases, *E. coli* isolates that were initially susceptible to tigecycline *in vivo* became tigecycline resistant after prolonged antimicrobial administration and, furthermore, *in vitro* the resistant isolates were found to produce carbapenemases: New Delhi metallo-β-lactamase 1 (NDM-1) ([@B17]) and *K. pneumoniae* carbapenemase 3 (KPC-3) ([@B18]). These carbapenemases are active against third-generation cephalosporins and carbapenems; therefore, the acquisition of tigecycline resistance likely confers an MDR phenotype. Stone et al. ([@B17]) reported the development of resistance *in vivo* after 53 days of tigecycline treatment, and Spanu et al. ([@B18]) reported resistance after 21 days of treatment. Despite these reports of development of tigecycline resistance among *E. coli* isolates, the current TEST study shows that tigecycline remains active against the majority of MDR *E. coli* isolates, and the TEST publication by Hoban et al. ([@B12]) reported that tigecycline was active against carbapenem-resistant *E. coli* isolates collected between 2004 and 2013.

By organism, the highest overall rates of multidrug resistance reported in the present study were among *A. baumannii* isolates, for which 44% of isolates collected globally were MDR. By year, the results presented in [Fig. 1](#fig1){ref-type="fig"} show an increase in the rates of MDR *A. baumannii* during the study period, from 23% (309/1,323) in 2004 to 63% (447/712) in 2014. The previous TEST publication by Garrison et al. ([@B19]) reported increasing global rates of MDR *A. baumannii* isolates between 2004 and 2007, and Mendes et al. ([@B14]) described a global increase in the rates of MDR *Acinetobacter* spp. between 2005 and 2009. Our report shows that multidrug resistance among *A. baumannii* isolates continues to increase; given the limited treatment options for infections caused by such organisms, this is a cause for concern.

The majority of MDR isolates collected globally were resistant to levofloxacin, with rates of resistance ranging from 83% of *E. aerogenes* isolates to 98% of *E. coli*. The World Health Organization (WHO) recently published a report on global antimicrobial resistance that included national data on rates of resistance from Africa, the Americas, Eastern Mediterranean, Europe, Southeast Asia, and the Western Pacific ([@B20]). In their report, resistance rates among *E. coli* isolates of greater than 50% were reported to fluoroquinolones in all regions except Europe. They also showed that infections caused by fluoroquinolone-resistant *E. coli* isolates were associated with increased mortality. Fluoroquinolone resistance has been linked with extended-spectrum β-lactamase production among the *Enterobacteriaceae* ([@B4], [@B6]); therefore, extended-spectrum β-lactamase production may be an indicator of multidrug resistance.

Although global surveillance studies, such as TEST, have reported important information on changes in antimicrobial activity and resistance, there are certain limitations to the data presented. One such limitation is the yearly variation in the numbers of participating centers. For example, the Asia-Pacific region stopped submitting isolates between 2010 and 2014. In this region, the rates of MDR *A. baumannii* isolates increased from 29% (14/49) in 2005 to 60% (97/161) during the final year of participation. The lack of isolates from this region after 2010 will have impacted the global results. Furthermore, the majority of centers participating in TEST were located in Europe and North America; therefore, changes in these regions could have had a greater impact on the global data.

Despite these limitations, the data presented in this study show that tigecycline has remained active against this global collection of Gram-negative pathogens. The collection of small numbers of tigecycline-resistant MDR *E. coli* isolates is of concern, however, and highlights the importance for the continued surveillance of tigecycline activity globally. The increasing rates of MDR *A. baumannii* isolates must also be monitored, and this information should be used to aid health care facilities in reducing MDR infections worldwide. Overall, more global studies of MDR pathogens are needed if the ongoing problem of antimicrobial resistance is to be addressed.

MATERIALS AND METHODS {#s3}
=====================

A total of 611 TEST centers submitted MDR Gram-negative isolates between 2004 and 2014. The numbers of centers located in each study region were as follows: Africa, 20; Asia-Pacific Rim, 52; Europe, 219; Latin America, 69; the Middle East, 23; North America, 228. Not all study centers submitted isolates during all study years. Centers from the Asia-Pacific Rim did not participate in the study after 2010. Isolates were collected from all body sites from patients with known hospital- or community-acquired infections.

MICs were determined in local laboratories using Clinical and Laboratory Standards Institute (CLSI) guidelines for the broth microdilution methodology ([@B21]). Antimicrobial susceptibility was assessed using breakpoints approved by the CLSI ([@B22]), except for tigecycline, for which the U.S. Food and Drug Administration (FDA) breakpoints were used ([@B8]). Breakpoints were not available for tigecycline against *A. baumannii* or *P. aeruginosa* isolates. Full methodology details for the TEST study have been published previously ([@B23]).

In the current study, multidrug resistance was defined as resistance to three or more classes of antimicrobial agents. The classes used to define MDR isolates among the *Enterobacteriaceae* were aminoglycosides (amikacin), β-lactams (ampicillin, amoxicillin-clavulanic acid, cefepime, ceftriaxone, or piperacillin-tazobactam), carbapenems (imipenem/meropenem), fluoroquinolones (levofloxacin), glycylcyclines (tigecycline), and tetracyclines (minocycline); the classes used to define MDR *A. baumannii* isolates were aminoglycosides (amikacin), β-lactams (cefepime, ceftazidime, ceftriaxone, or piperacillin-tazobactam), carbapenems (imipenem/meropenem), fluoroquinolones (levofloxacin), and tetracyclines (minocycline); the classes used to define MDR *P. aeruginosa* isolates were aminoglycosides (amikacin), β-lactams (cefepime, ceftazidime, or piperacillin-tazobactam), carbapenems (imipenem/meropenem), and fluoroquinolones (levofloxacin).

The Cochran-Armitage trend test was used to identify statistically significant changes in susceptibility between 2004 and 2014, with a cutoff value of *P* \< 0.01 to indicate significance, due to the large number of trend tests performed.
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